Literature DB >> 16160135

Tumor-induced osteomalacia.

Suzanne M Jan de Beur1.   

Abstract

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic form of renal phosphate wasting that results in severe hypophosphatemia, a defect in vitamin D metabolism, and osteomalacia. This debilitating disorder is illustrated by the clinical presentation of a 55-year-old woman with progressive fatigue, weakness, and muscle and bone pain with fractures. After a protracted clinical course and extensive laboratory evaluation, tumor-induced osteomalacia was identified as the basis of her clinical presentation. In this article, the distinctive clinical characteristics of this syndrome, the advances in diagnosis of TIO, and new insights into the pathophysiology of this disorder are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160135     DOI: 10.1001/jama.294.10.1260

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  74 in total

1.  Tumor-induced osteomalacia.

Authors:  Mala Kaul; Miriam Silverberg; Edward F Dicarlo; Robert Schneider; Anne R Bass; Doruk Erkan
Journal:  Clin Rheumatol       Date:  2007-01-16       Impact factor: 2.980

Review 2.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

3.  Diffuse pain, hypophosphatemia, and a subcutaneous nodule.

Authors:  Christine A Dewitt; Michael T Collins; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2007-09       Impact factor: 11.527

4.  Severe, reversible dysphagia and malnutrition in a patient with tumour-induced hypophosphataemia.

Authors:  Tone Ramsli; Jørgen Valeur; Mikkel Pretorius; Per Gerlyng
Journal:  BMJ Case Rep       Date:  2018-06-27

Review 5.  [Metabolic bone disease osteomalacia].

Authors:  M A Reuss-Borst
Journal:  Z Rheumatol       Date:  2014-05       Impact factor: 1.372

6.  Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis.

Authors:  M Odette Gore; Brian J Welch; Weidong Geng; Wareef Kabbani; Naim M Maalouf; Joseph E Zerwekh; Orson W Moe; Khashayar Sakhaee
Journal:  Kidney Int       Date:  2008-07-30       Impact factor: 10.612

7.  Following the forgotten phosphorus.

Authors:  Lekshmi T Nair; Leslie Dodd; Thomas J Weber
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

8.  Acquired hypophosphatemic osteomalacia is easily misdiagnosed or neglected by rheumatologists: A report of 9 cases.

Authors:  Ling Li; Shu-Xia Wang; Hong-Mei Wu; Dong-Lan Luo; Guang-Fu Dong; Yuan Feng; Xiao Zhang
Journal:  Exp Ther Med       Date:  2018-04-27       Impact factor: 2.447

9.  Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.

Authors:  Regina Goetz; Yuji Nakada; Ming Chang Hu; Hiroshi Kurosu; Lei Wang; Teruyo Nakatani; Mingjun Shi; Anna V Eliseenkova; Mohammed S Razzaque; Orson W Moe; Makoto Kuro-o; Moosa Mohammadi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

Review 10.  Fibrous dysplasia and fibroblast growth factor-23 regulation.

Authors:  Alison M Boyce; Nisan Bhattacharyya; Michael T Collins
Journal:  Curr Osteoporos Rep       Date:  2013-06       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.